新着情報

印刷

  • HOME
  • 新着情報
  • 【第46回がん研先端研究セミナー(2月5日)のお知らせ「Aging, Cellular Senescence, and Senolytic Agents」James L. Kirkland博士(Noaber Foundation Professor of Aging Research Director, Mayo Clinic Kogod Center on Aging)】

新着情報

【第46回がん研先端研究セミナー(2月5日)のお知らせ「Aging, Cellular Senescence, and Senolytic Agents」James L. Kirkland博士(Noaber Foundation Professor of Aging Research Director, Mayo Clinic Kogod Center on Aging)】

2018年01月16日

第46回がん研先端研究セミナー(2月5日)のお知らせ

 

演題:Aging, Cellular Senescence, and Senolytic Agents

 

演者:James L. Kirkland博士(Noaber Foundation Professor of Aging Research Director, Mayo Clinic Kogod Center on Aging)

 

抄録:Interventions targeting fundamental mechanisms of aging hold promise for enhancing healthspan by delaying, preventing, or alleviating age-related diseases and conditions as a group, instead of one-at-a-time, a theory termed the “geroscience hypothesis.” Among these fundamental mechanisms is cellular senescence. Senescent cells, which are resistant to apoptosis, can secrete a range of pro-inflammatory cytokines and chemokines, matrix-destroying proteases, factors that cause stem cell dysfunction, and hemostatic factors, the senescence-associated secretory phenotype (SASP). We developed senolytic agents drugs that selectively eliminate senescent cells by inhibiting the pro-survival Senescent Cell Anti-apoptotic Pathways (SCAPs) that protect these cells from apoptosis due to their own SASP. In pre-clinical animal experiments, intermittent administration of senolytic agents reduced frailty in progeroid mice, enhanced cardiac function in old age, reduced age- and high fat diet-related vascular dysfunction, alleviated bleomycin-induced pulmonary fibrosis, restored hepatic function and reduced liver fat and fibrosis in diet-induced liver steatosis, restored bone mass and strength by reducing resorption without impeding bone formation in age-induced osteoporosis, and alleviated dysfunction caused by radiation in mice. Thus, senolytic drugs are a new intervention that may delay, prevent, or treat multiple age- and chronic disease-related disorders. Early, proof-of-concept Phase 2 human clinical trials will be a critical step in translating these agents and others emerging from cell culture and animal preclinical studies into clinical practice. The goals of proof-of-concept trials for such interventions include generating preliminary signals of efficacy for age-related conditions that will test the value of proceeding to larger effectiveness trials. Such trials need to be designed to contribute data and biological samples to support basic research through strategic networks. Frameworks for proof-of-concept and later stage trials that target age-related chronic diseases, geriatric syndromes, or resilience to stressors will be considered. (Refs: Nat Commun. 2017, J Am Geriatr Soc. 2017, Nat Med. 2017, E Bio Medicine. 2017)

 

日時:2018年2月5日(月) 11:00〜12:00

 

場所:がん研有明病院・新棟レセプションルーム

 

連絡先:高橋 暁子(5351)

 

*外部の研究者のご来聴を歓迎いたします。尚、本セミナーの内容は専門的であり、医学・生物分野の研究に携わる方を対象としております。

 

 

 

このページのTOPへ